top of page

Shockwave Therapy for ED

2.jpg
How does it work?

 

LiSWT is administered with a wand-like device placed near different areas of the penis. A healthcare provider moves the device along parts of your penis for about 10-15 minutes while it emits gentle pulses. No anesthesia is needed.

​

The pulses trigger improved blood flow and tissue remodeling in the penis. Both of these changes can lead to erections sufficient for sex.

Pricing

 

Cost per treatment: $150.00

Exosome Injection: $1200.00

​

Shockwave Therapy for
Erectile Dysfunction and Peyronie's Disease

 

Low-intensity Shockwave Therapy (LiSWT) is a noninvasive therapy that's been used in orthopedics for years to help heal broken bones, injured ligaments and injured endons.

​

LiSWT has also been used to improve wound healing. Using targeted high-energy sound waves, LiSWT can speed up tissue repair and cell growth.

​

Erections rely on healthy blood flow to the penile tissue. LiSWT is viewed favorably as a way of repairing and strengthening blood vessels in the penis and improving blood flow. 

​

Increasing blood flow to the penis is the same goal of more traditional ED treatments, such as oral medications, including Sildenafil (Viagra) and Tadalafil (Cialis).

What is the protocol?
​

A course of LiSWT involves typically 6-10 treatments. Each treatment lasts approximately 10-15 minutes. Treatments are typically performed either once or twice weekly (no difference in outcomes have been demonstrated in studies performing this procedure one or twice weekly).

​

*The cost of each treatment is $150.00

​

Some patients note significant improvement after as few as four treatments. It is recommended that once a patient is satisfied with their erectile function, that treatments are terminated.

​

After 10 treatments, therapy is discontinued for at least two months, during which time there is continued vascular proliferation and improvement in erections.

​

After two months, if erectile function is not satisfactory, then an injection of Exosomes (stem cell derivatives) and five more LiSWT treatments will be recommended.

​

*The cost of an Exosome injection is $1200.00

What does the research say?

​

A 2019 review and meta-analysis found that erectile function significantly improved with LiSWT. Results were best among men with vasculogenic ED.

​

A 2010 pilot study found that among 20 men with vasculogenic ED, all experienced improved erectile function after six months of LiSWT treatments. Follow-up with the men found no adverse effects. 

​

Published: 21 January 2019

​

Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials

Ioannis Sokolakis & Georgios Hatzichristodoulou 

International Journal of Impotence Research volume 31, pages177–194(2019)

 

Abstract:

​

The efficacy of low intensity extracorporeal shock wave therapy (LI-ESWT) for erectile dysfunction (ED) has received hard criticism and recently published meta-analyses were not able to provide further insights, nor specific recommendations. The aim of this systematic review and meta-analysis is to evaluate the efficacy of LI-ESWT for ED, identify the ideal treatment population and treatment protocol, and provide recommendations for future research in the field. A systematic research for relevant clinical studies published from January 2010 to September 2018 was performed, using the following databases: Medline, Embase, The Cochrane Library, Scopus, and Web of Science. Only clinical studies that investigated the efficacy of LI-ESWT for ED only, and reported primary outcomes using IIEF-EF scores/questionnaires were included. Both, randomised controlled trials (RCTs) and cohort studies were included, but the meta-analysis was performed only for sham-controlled RCTs. Ten RCTs including 873 patients were selected for the meta-analysis. Pooling data of these studies showed that LI-ESWT could significantly improve erectile function in men with ED regarding both patient-subjective outcomes (IIEF-EF: +3.97; 95% CI [2.09–5.84]; p < 0.0001, EHS ≥ 3: OR: 4.35; 95% CI [1.82–10.37]; p = 0.0009) and patient-objective outcomes (peak systolic velocity: +4.12; 95% CI [2.30–5.94]; p < 0.00001). In conclusion, the present meta-analysis provided results showing that LI-ESWT significantly improves erectile function in patients with vasculogenic ED.

bottom of page